Adaptimmune makes executive hires from GSK
pharmafile | March 5, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Adaptimmune, Adrian Rawcliffe, Rafael Amado
UK and US clinical-stage biotech firm Adaptimmune has increased its senior team with the appointment of Dr Rafael Amado as chief medical officer, and Adrian Rawcliffe as chief financial officer.
Amado (pictured) will lead Adaptimmune’s clinical strategy and assume responsibility for its clinical trials across the US and Europe under a strategic collaboration with GlaxoSmithKline. He will also lead the development of the company’s pipeline.
Prior to joining Adaptimmune Amado served as senior VP and head of oncology R&D at GSK, which he joined in 2008 as VP of clinical development. Before GSK Amado was an executive director of therapeutic oncology at Amgen.
Rawcliffe will lead Adaptimmune’s financial management along with compliance and risk management. He also joins from GSK where he was senior VP in finance for its North American business.
Prior to this Rawcliffe held a variety of senior finance and business development roles at GSK which he joined in 1998, that also include being managing partner and president of SR One, GSK’s venture-capital business.
“I am delighted that Rafael and Ad are joining the company”, says James Noble, chief executive of Adaptimmune. “Each brings a wealth of invaluable experience to complement the expertise of our existing senior management team. I am confident that Rafael and Ad will play key roles as we continue to progress our clinical programs and strengthen our strategic partnership with GSK, as well as drive the development of our internal pipeline.”
Related Content
Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour
Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given …
Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial
Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a …
GSK and Adaptimmune expand R&D collaboration
Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run …
